地塞米松对晚期非小细胞肺癌化疗患者的临床效果

Clinical effect of dexamethasone on chemotherapy in patients with advanced non-small cell lung cancer

目的探讨地塞米松对晚期非小细胞肺癌化疗患者的临床效果。方法选取2016年1~12月我院收治的晚期非小细胞肺癌(NSCLC)患者80例,随机分为两组,对照组40例患者应用化疗治疗,研究组40例患者联合应用地塞米松治疗。比较两组的治疗效果。结果两组患者治疗有效率比较差异无统计学意义(P>0.05);治疗前两组患者的HIF-1α及VEGF水平比较差异无统计学意义(P>0.05);治疗后均得到一定改善,研究组显著低于对照组(P<0.05);治疗前两组患者的免疫功能比较差异无统计学意义(P>0.05),治疗后均得到一定改善,研究组显著优于对照组(P<0.05)。结论晚期NSCLC化疗患者联合应用地塞米松有利于提高患者免疫功能,临床上应当推广应用。

Objective To investigate the clinical effect of dexamethasone on chemotherapy in patients with advanced non-small cell lung cancer （NSCLC）.Methods Eighty patients with advanced NSCLC admitted into our hospital from January to December in 2016 were enrolled and randomly divided into two groups.40 cases of the control group was used with chemothrapy,while 40 cases of the research group was added with dexamethasone.The therapeutic effect was compared in both groups.Results There was no statistically significant difference in short-term effective rate between the two groups （P〉0.05）.Before therapy,the levels of HIF-1α and VEGF had no statistically significant difference （P〉 0.05）.After treatment,they were both improved,and the levels in the research group were much lower compared with those in the control group （P〈0.05）.Before treatment,the immune function in the two groups had no statistically signifi- cant difference （P〉0.05）.After treatment,they were both improved,and improvement in the research group was superior to that in the control group （P〈0.05）.Conclusion For patients with advanced NSCLC,combination of dexametbasone is beneficial to improve patients＇ immune function,which should be recommended for clinical application.